Paul Reider has followed Coherus BioSciences’ last biosimilar product out the door. | Paul Reider has followed Coherus ...

India's pharma and healthcare sector demonstrates resilient investor interest, marked by a 34% year-on-year increase in deal ...

DelveInsight's "Uterine Sarcoma Market Insights, Epidemiology, and Market Forecast- 2032" report delivers an in-depth ...

Dr. Kiran Mahasuar, Asst Professor at IMT Ghaziabad, writes why branded generics may still dominate volumes, but the real ...

5. ‘Pharmaceutical Industry: AI for Faster, Smarter Drug Development’ India’s pharma leaders are using AI to accelerate every phase of the drug lifecycle—from molecule discovery to market ...

Ahmedabad: Intas Pharma has announced the appointment of Sarang Pande as Vice President - Digital Manufacturing & Industry Automation. In a recent LinkedIn post, the pharmaceutical major welcomed ...

Claim your 7-day free trial now. MIRA Pharmaceuticals, Inc. MIRA on Wednesday released data demonstrating the efficacy of the oral ketamine analog, Ketamir-2, in a validated animal model of ...

“We need to make semiconductors.” The investigation into pharmaceutical imports includes ingredients used to make such drugs and touches on many of the same aspects of relying on imports to ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up to ...

The trade policy whiplash continues as the US flags plans to levy new tariffs against imported pharmaceutical products and semiconductors. The US is heavily reliant on chip imports, especially from ...

Bharat Biotech, the Hyderabad-based firm that developed Covaxin during the Covid-19 pandemic, was the biggest pharmaceutical donor – it alone gave the BJP Rs 50 crore. Four other companies – Zydus ...

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals under an asset purchase agreement signed by the companies in December 2024 for up ...